125 related articles for article (PubMed ID: 37414247)
21. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
22. Twice-weekly hypofractionated intensity-modulated radiotherapy for localized prostate cancer with low-risk nodal involvement: toxicity and outcome from a dose escalation pilot study.
Zilli T; Jorcano S; Rouzaud M; Dipasquale G; Nouet P; Toscas JI; Casanova N; Wang H; Escudé L; Mollà M; Linero D; Weber DC; Miralbell R
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):382-9. PubMed ID: 20884129
[TBL] [Abstract][Full Text] [Related]
23. Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS-1 trial.
Katayama S; Striecker T; Kessel K; Sterzing F; Habl G; Edler L; Debus J; Herfarth K
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):926-33. PubMed ID: 25216858
[TBL] [Abstract][Full Text] [Related]
24. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer.
Lock M; Best L; Wong E; Bauman G; D'Souza D; Venkatesan V; Sexton T; Ahmad B; Izawa J; Rodrigues G
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1306-15. PubMed ID: 20708855
[TBL] [Abstract][Full Text] [Related]
25. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
26. Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis.
Tamihardja J; Schortmann M; Lawrenz I; Weick S; Bratengeier K; Flentje M; Guckenberger M; Polat B
Strahlenther Onkol; 2021 Feb; 197(2):124-132. PubMed ID: 32833036
[TBL] [Abstract][Full Text] [Related]
27. Hypofractionated intensity-modulated simultaneous integrated boost and image-guided radiotherapy in the treatment of high-risk prostate cancer patients: a preliminary report on acute toxicity.
Valeriani M; Carnevale A; Osti MF; Minniti G; De Sanctis V; Agolli L; Bracci S; Enrici RM
Tumori; 2013; 99(4):474-9. PubMed ID: 24326835
[TBL] [Abstract][Full Text] [Related]
28. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.
Miralbell R; Mollà M; Rouzaud M; Hidalgo A; Toscas JI; Lozano J; Sanz S; Ares C; Jorcano S; Linero D; Escudé L
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):50-7. PubMed ID: 19910135
[TBL] [Abstract][Full Text] [Related]
29. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
Kupelian PA; Thakkar VV; Khuntia D; Reddy CA; Klein EA; Mahadevan A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1463-8. PubMed ID: 16169683
[TBL] [Abstract][Full Text] [Related]
30. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
[TBL] [Abstract][Full Text] [Related]
31. Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapy.
Aizawa R; Takayama K; Nakamura K; Inoue T; Yamasaki T; Kobayashi T; Akamatsu S; Ogawa O; Mizowaki T
Int J Clin Oncol; 2020 Apr; 25(4):713-719. PubMed ID: 31820209
[TBL] [Abstract][Full Text] [Related]
32. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer.
Spratt DE; Pei X; Yamada J; Kollmeier MA; Cox B; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):686-92. PubMed ID: 22795805
[TBL] [Abstract][Full Text] [Related]
33. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
34. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
35. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
36. Moderate Hypofractionated Protracted Radiation Therapy and Dose Escalation for Prostate Cancer: Do Dose and Overall Treatment Time Matter?
Kountouri M; Zilli T; Rouzaud M; Dubouloz A; Linero D; Escudé L; Jorcano S; Miralbell R
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):272-9. PubMed ID: 26853336
[TBL] [Abstract][Full Text] [Related]
37. The 5-year outcomes of moderately hypofractionated radiotherapy (66 Gy in 22 fractions, 3 fractions per week) for localized prostate cancer: a retrospective study.
Hashimoto Y; Motegi A; Akimoto T; Mitsuhashi N; Iizuka J; Tanabe K; Ishii Y; Kono S; Izumi S; Karasawa K
Int J Clin Oncol; 2018 Feb; 23(1):165-172. PubMed ID: 28758177
[TBL] [Abstract][Full Text] [Related]
38. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.
Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M
Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594
[TBL] [Abstract][Full Text] [Related]
39. A Japanese multi-institutional phase II study of moderate hypofractionated intensity-modulated radiotherapy with image-guided technique for prostate cancer.
Nakamura K; Nihei K; Saito Y; Shikama N; Noda SE; Hara R; Imagumbai T; Mizowaki T; Akiba T; Kunieda E; Someya M; Ohga S; Kawamori J; Kozuka T; Ota Y; Inaba K; Kodaira T; Itoh Y; Funakoshi K; Kagami Y
Int J Clin Oncol; 2024 Jun; 29(6):847-852. PubMed ID: 38630382
[TBL] [Abstract][Full Text] [Related]
40. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes.
Patel N; Faria S; Cury F; David M; Duclos M; Shenouda G; Ruo R; Souhami L
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):534-9. PubMed ID: 23597418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
